Baxter Says Generic Co. Infringed Hypertension Med Patent

Law360, Los Angeles (October 22, 2013, 3:41 PM EDT) -- Baxter International Inc. on Tuesday hit HQ Specialty Pharma Corp. with a lawsuit in New Jersey federal court alleging HQ's proposed generic version of its blood pressure and heart rhythm disorder drug Brevibloc infringes two of its patents. 

In its complaint, Deerfield, Ill.-based Baxter alleges Paramus, N.J.-based HQ's submission to the Food and Drug Administration of a new drug application for a generic version of Brevibloc constitutes infringement of its U.S. Patent Numbers 6,310,094 and 6,528,540. 

"Baxter has no adequate remedy at law for HQ Specialty...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.